PPCB — Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: AU
- Exchange: NASDAQ Capital Market
- Employees: 1
- Website: https://www.propanc.com
Latest SEC filings for PPCB
- S-1 — 2026-10-05
- 10-K — 2026-09-25
- S-1 — 2026-07-17
- S-1 — 2026-07-17
- 8-K — 2026-07-14
- 10-Q — 2026-05-14
- EFFECT — 2026-04-21
- S-1 — 2026-04-10
- S-1 — 2026-04-10
- 424B3 — 2026-03-06
Latest PPCB news
- — Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer (globenewswire.com)
- — Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib (globenewswire.com)
- — Propanc Biopharma, Inc. GAAP EPS of -$17.62 (seekingalpha_market)
- — Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results (globenewswire.com)
Educational tool only — not investment advice.